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Background: Cardiotrophin-1 (CT-1), a cytokine produced by cardiomyocytes and non-cardiomyocytes in conditions of
stress, can be used as a biomarker of left ventricular hypertrophy and dysfunction in hypertensive patients. Hypertension
is one of the main adverse events in the third and last phase of Fabry’s disease (FD). We measured CT-1 in order to
examine its correlation with the vascular and cardiac alterations at different ages and assess its potential for use as a
biomarker of hypertension in FD.
Findings: The level of CT-1 was clearly higher in hypertensive adults than in adult FD patients. FD patients show a
small, non-significant decrease in plasma CT-1 with age, while in hypertensive patients CT-1 in plasma rises strongly
and highly significantly with age.
Conclusions: CT-1 can be considered a good biomarker of the progression of hypertension with age, but particular care
is needed when following hypertension in FD patients, since CT-1 does not correlate the same way with this disease.
Keywords: Fabry disease (FD), Hypertension, Cardiotrophin-1 (CT-1)Findings
Introduction
Cardiotrophin-1 (CT-1) is a member of the interleukin-6
superfamily and activates gp130-dependent signaling,
stimulating the (JACK/STAT) pathway and cardiac hyper-
trophic myocytes [1]. In conditions of stress, CT-1 acti-
vates different pathways in cardiac hypertrophic myocytes,
leading to myocardial fibrosis, and contributing to the
pathogenesis of hypertensive heart disease [2].
A recent study indicated that circulating CT-1 correlates
with cardiac hypertrophy and vascular damage in hyper-
tensive patients so it could serve as a biomarker of left
ventricular hypertrophy and dysfunction in these cases
[2,3]. CT-1 could therefore offer a new clinical and
diagnostic approach for monitoring hypertension and
its pathological effects [3-7].
Hypertension is one of the main adverse events occur-
ring in the last phase of Fabry’s disease (FD). FD is a rare* Correspondence: mmcorsi@unimi.it
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unless otherwise stated.X-linked hereditary lysosomal storage disorder due to
deficiency of α-galactosidase A (α-Gal A), resulting in the
accumulation of globotriaosylceramide (Gb3), which leads
to an inflammatory response [8] leading to a variety of
clinical manifestations, ranging from cerebrovascular dis-
eases to renal injury and cardiomyopathy [9-17].
FD nephropathy progresses with the severity of the
disease, eventually resulting in chronic kidney disease,
leading to hypertension. Usually untreated patients show
three clinical phases of FD nephropathy, according to
age [17]. In the first phase (childhood and adolescence)
there is glomerular hyperfiltration; in the second (adults)
there is renal involvement with proteinuria and lipiduria,
and in the third phase severe renal and cardiovascular
complications arise, leading to hypertension [14].
The vascular aspect of FD has been described [18,19]
but there is still no ‘gold standard’ for monitoring the
complications of hypertension. We therefore measured
CT-1 in people with and without FD, developing hyper-
tension with age, in order to examine the correlation
between this cytokine and the involvement of the vas-
cular and cardiac system at different ages and assess
the potential for using it as a biomarker of hypertension
in FD. CT-1 was positively associated with age in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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took the opposite direction. The findings do indicate that
CT-1 could be a good biomarker to monitor the progres-
sion of hypertension with age, but particular care is
needed in FD patients because its levels do not correlate
the same way with this disease.
Patients and methods
Patients
The population study comprised 18 FD (10 male and 8
female) and 34 (20 male and 14 female) not-FD hyper-
tensive people, divided into two groups according to age
(young, 3-30 years; adults, 40-65 years) and gender
(young FD: 4 male and 4 female, young hypertensive: 8
male and 7 female, adult FD: 6 male and 4 female, adult
hypertensive 12 male and 11 female. All FD patients had
a confirmed diagnosis based on enzyme analysis and
genotyping, and presented borderline hypertension at
the time of the study. The hypertension population was
defined as having systolic blood pressure (BP) ≥140 mm
Hg and/or diastolic BP ≥90 mm Hg in three consecutive
measurements. Fabry subjects present little if noneFigure 1 Cardiotrophin-1 plasma levels in Fabry disease (FD) and hyper
(CT-1) plasma levels in young male and female (3-20 years old) hypertensive (
pale gray bar female). Panel B: Cardiotrophin-1 (CT-1) plasma levels in adult m
bar female) and FD patients (white bar male/pale gray bar female). Panel C: C
old, black bar male/dark gray bar female) and adult male and female (30-65 y
Panel D: Cardiotrophin-1 (CT-1) plasma levels in young male and female (3-20
female (30-65 years old, white bar male/ pale gray bar female) FD patients.ventricular hyperthopy, with Left ventricular wall below
the pathological threshold (<12 mm).
CT-1 assay
Plasma EDTA was obtained from all the participants.
After centrifugation at 1500 g for 15 min, samples were
rapidly frozen and stored at -20°C until assay. Plasma
CT-1 was determined by enzyme-linked immunosorbent
assay (ELISA) (BioVendor Research and Diagnostic Prod-
ucts, Brno, Czech Republic).
Statistical analysis
The results are presented as mean ± standard deviation
(SD). For between-groups comparisons we used Student’s
two-tailed t test, taking p <0.05 as significant. Analyses
were done with GraphPad Software (San Diego, CA).
Results
CT-1 was measured in FD and hypertensive patients
matched by age (Figure 1). Panel A depicts CT-1 plasma
levels in young patients, which were slightly but signifi-
cantly higher in those with hypertension (FD youngtensive patients matched for age and sex. Panel A: Cardiotrophin-1
black bar male/dark gray bar female) and FD patients (white bar male/
ale and female (30-65 years old) hypertensive (black bar male/dark gray
ardiotrophin-1 (CT-1) plasma levels in young male and female (3-20 years
ears old, white bar male/pale gray bar female) hypertensive patients.
years old, black bar male/dark gray bar female) and adult male and
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7.93 Fmol/mL, p < 0.05). Panel B shows the CT-1 plasma
levels in adults. CT-1 was clearly and highly significantly
higher in hypertensive than FD adults (FD adults 6.14 ±
3.62 Fmol/mL vs. hypertensive adults 29.53 ± 3.92 Fmol/
mL; p < 0.0001).
Figure 2 illustrates the CT-1 levels with age in the FD
(panel A) and hypertensive patients (panel B). In FD
patients plasma CT-1 decreased slightly but not signifi-
cantly with age whereas in hypertensive patients the
plasma levels showed a marked, highly significant increase
with age (young vs. adults p < 0.0001). Data were divided
and analyzed according also to the gender. No significative
difference were observed between genders in any case.
Discussion
The main finding of this study is that CT-1 is positively
associated with age in hypertensive patients, while in FD
patients plasma levels take the opposite direction.
In hypertensive patients there was an age-related ten-
dency for CT-1 to rise, younger patients having lower
levels than adults. This agrees with previous reports in-
dicating CT-1 as involved in left ventricular hypertrophy
and dysfunction in hypertensive patients [2,3,5] and could
therefore be a good potential biomarker to monitor the
development of hypertension. Since hypertension is a
progressive condition that evolves with age, monitoring
patients is very important for the clinical approach and
treatment. In FD too there is a pathological progression
with adult age, particularly in the cardiovascular system,
leading to hypertension [11,14].
Our study is, to our knowledge, the first comparing
circulating CT-1 level in FD and hypertensive patients,
particularly in relation to age. While in non-FD hyperten-
sive patients CT-1 plasma levels rose with age, FD patients
showed the opposite pattern, young patients having higher
CT-1 levels than adults. This agrees with a generally lower
level of CT-1 in plasma of FD patients than hypertensive
patients (as shown in Fig 1) . Thus, while CT-1 is consid-
ered a good biomarker in hypertensive patients for moni-
toring the cardiac dysfunction, FD patients develop
hypertension differently, probably not involving the
CT-1 mediated pathway. FD adults develop a variety of
complications, being a consequence of progressive renal
injury [20]. It is therefore possible that hypertension
develops in FD following a different pathogenic mechan-
ism from non-FD hypertensive patients, mainly related to
cardiac dysfunction and, therefore, involving CT-1. CT-1
results were also divided and analyzed according to the
gender in both FD and hypertensive patients, but no sig-
nificative difference were observed between genders both
in young and adult subject.
Our study has some limitations, including the small
samples because FD is a rare disease, and the FD patientsdid not have severe cardiac complications. They also only
had mild hypertension at the time, so we probably need
patients with more serious hypertension to investigate the
role of CT-1 further. For these reasons, our findings must
be considered simply as preliminary observations that
need thorough investigation to understand the potential
for CT-1 as a hypertension biomarker in FD patients
better.
In conclusion, CT-1 can probably be considered a good
biomarker to monitor the progression of hypertension
with age in association with left ventricular hypertrophy
[21], but particular attention is needed when monitoring
the development of hypertension in FD patients, where
CT-1 does not correlate with this disease.Consent
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